|
The manufacturer received information alleging that a patient using an everflo oxygen concentrator experienced insufficient oxygen delivery during clinical and therapeutic use.The patient's daughter reported that the patient's peripheral oxygen saturation (spo2) decreased to 70% for an unspecified period of time, with no device alarm sounding during the alleged event.The patient's condition reportedly deteriorated, resulting in ems transport to a hospital and subsequent admission.The device underwent an initial inspection by a technical service team, including testing of the pressure delivery system and alarm conditions related to flow and fio2.The device passed the preliminary testing, and the alarms functioned as intended during simulated low-flow and decreased fio2 conditions.It was noted that the device had been in use for approximately 5,100 hours over the past 7 months (equivalent to 24 hours per day) and had accumulated a corresponding amount of dust.The manufacturer's investigation is ongoing.A follow-up report will be submitted when the manufacturer's investigation is complete.
|